Literature DB >> 19764836

Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans.

Trine Schnedler Clausen1, Peter Kaastrup, Bente Stallknecht.   

Abstract

BACKGROUND: Insertion of an insulin catheter for continuous subcutaneous insulin infusion into the subcutaneous adipose tissue (SAT) causes a tissue trauma that may have consequences for insulin absorption. We evaluated the importance of insulin catheter wear-time on subcutaneous adipose tissue blood flow (ATBF) and absorption of the rapid-acting insulin analog insulin aspart over a period of 4 days.
METHODS: Teflon insulin catheters (Medtronic, Minneapolis, MN) were inserted into the abdominal SAT of 10 healthy men without diabetes (mean +/- SEM age, 23.0 +/- 1.1 years; body mass index, 22.1 +/- 0.7 kg/m(2)) and connected to an insulin pump delivering a constant rate of isotonic saline for 4 days. Subjects participated in four study days (days 0, 1, 2, and 4) during which ATBF around the catheter tip was measured by (133)Xe clearance and absorption of an insulin aspart bolus (0.1 U/kg) was measured for 4 h.
RESULTS: ATBF increased from day 0 to day 2 after catheter insertion (2.6 +/- 0.6 to 4.5 +/- 0.8 mL/100 g/min; P = 0.030). By day 4, ATBF had returned to day 0 level. Time to peak plasma insulin aspart concentration after bolus administration decreased with catheter wear-time from 55 +/- 3 min on day 0 to 45 +/- 4 min on day 4 (P = 0.019). Neither peak plasma concentration nor area under the curve of insulin aspart changed significantly.
CONCLUSIONS: Insertion of a Teflon insulin catheter into the SAT results in increased ATBF and faster absorption of insulin aspart in a period of 4 days without any change in the total amount of insulin aspart absorbed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19764836     DOI: 10.1089/dia.2009.0058

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  16 in total

1.  CSII: Longer Catheter Usage Time, a Reasonable Goal.

Authors:  Jean-Luc Ardilouze; Julie Ménard; Fernand Gobeil; Maude Gagnon-Auger; Ghislaine Houde; Marie-Hélène Pesant; Rémi Rabasa-Lhoret; Jean-Patrice Baillargeon
Journal:  J Diabetes Sci Technol       Date:  2016-06-28

Review 2.  Clinical requirements for closed-loop control systems.

Authors:  William L Clarke; Eric Renard
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

3.  Patch pump versus conventional pump: postprandial glycemic excursions and the influence of wear time.

Authors:  Yoeri M Luijf; Sabine Arnolds; Angelo Avogaro; Carsten Benesch; Daniela Bruttomesso; Anne Farret; Lutz Heinemann; Jerome Place; Eric Renard; Rachele Scotton; J Hans DeVries
Journal:  Diabetes Technol Ther       Date:  2013-05-07       Impact factor: 6.118

4.  Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase.

Authors:  Douglas B Muchmore; Daniel E Vaughn
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

5.  Capsule thickness correlates with vascular density and blood flow within foreign-body capsules surrounding surgically implanted subcutaneous devices.

Authors:  Carlo R Bartoli; Menaka M Nadar; John J Godleski
Journal:  Artif Organs       Date:  2010-10       Impact factor: 3.094

6.  Performance and acceptability of a combined device for insulin infusion and glucose sensing in the home setting.

Authors:  Kirsten Nørgaard; John Shin; John B Welsh; Hans Gjessing
Journal:  J Diabetes Sci Technol       Date:  2015-01-14

Review 7.  Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion.

Authors:  Lutz Heinemann; Lars Krinelke
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

Review 8.  Undeniable need for ultrafast-acting insulin: the pediatric perspective.

Authors:  Eda Cengiz
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

9.  Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes.

Authors:  Andrew W Karlin; Trang T Ly; Laura Pyle; Gregory P Forlenza; Laurel Messer; R Paul Wadwa; Daniel J DeSalvo; Sydney L Payne; Sarah Hanes; Paula Clinton; David M Maahs; Bruce Buckingham
Journal:  Diabetes Technol Ther       Date:  2016-05-26       Impact factor: 6.118

10.  Using Insulin Infusion Sets in CSII for Longer Than the Recommended Usage Time Leads to a High Risk for Adverse Events: Results From a Prospective Randomized Crossover Study.

Authors:  Andreas Pfützner; Daniela Sachsenheimer; Marco Grenningloh; Matthias Heschel; Lene Walther-Johannesen; Rabi Gharabli; David Klonoff
Journal:  J Diabetes Sci Technol       Date:  2015-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.